{"id":3164,"date":"2026-09-14T07:45:00","date_gmt":"2026-09-14T11:45:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3164"},"modified":"2026-09-15T19:59:16","modified_gmt":"2026-09-15T23:59:16","slug":"tbs-2025-cleared-to-enter-post-menin-mutnpm1-aml","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3164","title":{"rendered":"TBS-2025 Cleared to Enter Post-Menin mutNPM1 AML"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

TuHURA Biosciences<\/p>\n

Event Type<\/strong><\/p>\n

IND Clearance (Study May Proceed)<\/p>\n

Modality<\/strong><\/p>\n

Monoclonal Antibody (VISTA Checkpoint Inhibitor)<\/p>\n

Asset<\/strong><\/p>\n

TBS-2025<\/p>\n

Target<\/strong><\/p>\n

VISTA<\/p>\n

Disease Area<\/strong><\/p>\n

Relapsed\/Refractory Acute Myeloid Leukemia With Mutant NPM1, Post-Menin Inhibitor<\/p>\n

Summary<\/h4>\n

FDA issued a “study may proceed” notice for a Phase Ib study of TBS-2025, a VISTA-inhibiting monoclonal antibody, in relapsed or refractory acute myeloid leukemia with mutant NPM1 after failure of or relapse on a menin inhibitor. The initial study will evaluate safety and dose escalation before dose optimization. The regulatory milestone opens human testing in a molecularly defined, high-need setting, but all disclosed efficacy support is preclinical and the sponsor’s accelerated-approval discussion is conditional.<\/p>\n

The issuer release was published September 14, 2026 at 7:45 a.m. Eastern and recovered during the September 15 morning source-gap reconciliation at approximately 8:55 a.m. Eastern. The planned study begins with monotherapy dose escalation and may expand only if activity is encouraging. No trial identifier, first-patient date, dose levels, biomarker assay, or human safety data were disclosed.<\/p>\n

TuHURA reports that mutant NPM1 can drive VISTA expression and an immunosuppressive phenotype, and that VISTA blockade restored immune activity and reduced leukemia burden in murine models. Those findings support a testable mechanism but do not establish target dependence, human exposure, or response after menin-inhibitor resistance.<\/p>\n

Deep Analysis<\/h4>\n

One interpretation is that VISTA-mediated immune escape defines a tractable vulnerability in post-menin mutNPM1 AML. Molecular selection, a resistance-linked treatment sequence, and animal activity support that view. Contradicting evidence includes the absence of human VISTA-biomarker distributions, pharmacodynamic thresholds, and evidence that prior menin inhibition actually creates or enriches dependence. A second interpretation is that the narrow entry population is a development strategy around a biologically plausible marker rather than a validated responder group. That fits the early dose-escalation design; however, the explicit genotype and treatment-history criteria create a focused falsification test.<\/p>\n

Company and Product Background<\/h4>\n

TuHURA is developing immuno-oncology programs intended to address primary and acquired resistance. AML is a clonal myeloid malignancy with poor outcomes after relapse. NPM1 mutation is common in AML and creates a distinct transcriptional and immunologic state. VISTA is an inhibitory checkpoint expressed strongly in myeloid cells and suppressive myeloid populations; blocking it may enhance antitumor immunity but may also produce inflammatory or hematologic toxicity.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • IND clearance is a meaningful start, not evidence that VISTA blockade works in AML. The valuable feature is the prospectively defined post-menin mutNPM1 population.<\/li>\n
  • Upgrades with:<\/strong> reproducible VISTA expression in post-menin patient samples, on-treatment receptor occupancy and immune activation, responses linked to biomarker change, and tolerable myeloid and inflammatory effects.<\/li>\n
  • Downgrades with:<\/strong> heterogeneous expression, no pharmacodynamic engagement, rapid immune escape, or responses unrelated to genotype.<\/li>\n
  • Falsified if:<\/strong> adequate exposure and target engagement fail to produce biological or clinical activity in biomarker-confirmed disease.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    IND clearance is a meaningful start, not evidence that VISTA blockade works in AML. The valuable feature is the prospectively defined post-menin mutNPM1 population; the decisive question is whether the proposed immune-escape mechanism is present and reversible in human marrow after contemporary therapy.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal strength:<\/strong> 4\/5 \u2014 a first-in-human path in a molecularly defined, post-menin AML population. Importance:<\/strong> Uncertain \u2014 regulatory clearance is positive, but clinical activity and tolerability are unknown. Confidence:<\/strong> High on facts (the sponsor confirmed FDA clearance and the planned design); low-moderate on interpretation (mechanistic support is preclinical and the human biomarker is unvalidated).<\/p>\n","protected":false},"excerpt":{"rendered":"

    FDA issued a \u201cstudy may proceed\u201d notice for a Phase Ib study of TBS-2025, a VISTA-inhibiting monoclonal antibody, in relapsed or refractory acute myeloid leukemia with mutant NPM1 after failure of or relapse on…<\/p>\n","protected":false},"author":1,"featured_media":3168,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[76,768,767],"class_list":["post-3164","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-acute-myeloid-leukemia","tag-tuhura-biosciences","tag-vista"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3164","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3164"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3164\/revisions"}],"predecessor-version":[{"id":3186,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3164\/revisions\/3186"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3168"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3164"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3164"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3164"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}